FDA approves new Omnicef (Cefdinir) oral suspension dosage for pediatric use
Abbott Laboratories announced today that a new FDA approved 250mg/5m dosing option of the antibiotic Omnicef (generic cefdinir) Oral Suspension (OS) is available for use in pediatric patients six months to 12 years old. The more concentrated 250mg/5mL formulation allows parents to administer fewer teaspoons per dose of the antibiotic to their children. When using [...]
Read User's Comments